Newly Diagnosed Glioblastoma Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Newly Diagnosed Glioblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled1 locationNCT07326566
Recruiting
Phase 1Phase 2

New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study

Newly Diagnosed Glioblastoma
Assistance Publique - Hôpitaux de Paris35 enrolled5 locationsNCT06622434
Recruiting
Phase 1

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Glioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme
CHA University10 enrolled1 locationNCT07143812
Recruiting
Phase 2

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

Newly Diagnosed Glioblastoma
Duke University92 enrolled1 locationNCT06816927
Recruiting
Phase 2

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Glioblastoma MultiformeNewly Diagnosed GlioblastomaGlioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype+1 more
Northwestern University25 enrolled1 locationNCT05864534
Recruiting
Phase 2

G-CSF After Chemo-radiation in Patients With Glioblastoma

Glioblastoma (GBM)MGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme
Massachusetts General Hospital60 enrolled1 locationNCT06649851
Recruiting
Phase 3

Anterior Temporal Lobectomy in Temporal Glioblastoma

Newly Diagnosed GlioblastomaTemporal Lobe
University Hospital, Bonn178 enrolled1 locationNCT07021339
Recruiting
Early Phase 1

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Newly Diagnosed Glioblastoma
Swedish Medical Center10 enrolled1 locationNCT05380349
Recruiting
Phase 4

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

Newly Diagnosed Glioblastoma
Medical University of Silesia36 enrolled1 locationNCT05235737